Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced that the first patients have been enrolled in two global Phase III clinical trials — MINT-E (NCT07018700 ...
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has launched flagship products XEOMIN ® (incobotulinumtoxinA) and RADIESSE ® in China. With this expansion into the world’s ...
“The enrollment of the first patients in the MINT trials marks an important milestone as we aim to address persistent gaps in migraine care by advancing a new neurotoxin option for patients.” MINT-E ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback